Calculate the Mantle Cell Lymphoma International Prognostic Index (MIPI and MIPI-c) for risk stratification, survival estimation, and treatment guidance.
The Mantle Cell Lymphoma International Prognostic Index (MIPI) is the validated prognostic scoring system for mantle cell lymphoma — an aggressive B-cell non-Hodgkin lymphoma that accounts for approximately 6% of all NHL cases in the United States. Developed by Hoster et al. (Blood, 2008), the MIPI incorporates four readily available clinical parameters: age, ECOG performance status, LDH level, and white blood cell count.
The MIPI stratifies patients into three risk groups with markedly different survival outcomes. Low-risk patients (MIPI < 5.7, ~44% of patients) have excellent 5-year survival approaching 75% with modern chemoimmunotherapy and maintenance rituximab. High-risk patients (MIPI ≥ 6.2, ~21% of patients) have median overall survival of only 29 months despite standard therapy — a population that benefits most from intensive approaches including autologous stem cell transplant, BTK inhibitors, and clinical trials.
The MIPI-c (combined biologic MIPI) integrates the Ki-67 proliferation index for enhanced prognostication. Ki-67 > 30% independently predicts poor outcomes and can reclassify patients between risk groups. Additionally, blastoid/pleomorphic morphology and TP53 mutations confer adverse prognosis regardless of the MIPI score.
The MIPI is the only validated prognostic index for mantle cell lymphoma and is recommended by NCCN, ESMO, and EHA guidelines for risk stratification. Accurate risk assessment guides treatment intensity — from observation for indolent disease to intensive chemoimmunotherapy with ASCT for high-risk fit patients. Keep these notes focused on your operational context. Tie the context to the calculator’s intended domain.
MIPI = 0.03535 × age (years) + 0.6978 (if ECOG ≥ 2) + 1.367 × log₁₀(LDH/ULN) + 0.9393 × log₁₀(WBC × 10⁹/L × 1000). Low risk < 5.7, Intermediate 5.7–6.2, High ≥ 6.2.
Result: MIPI 6.38 — High Risk, median OS ~29 months, 5-year OS ~20%
A 65-year-old with ECOG 1, LDH 1.4× ULN, and WBC 8.5 scores 6.38 on the MIPI, placing them in the high-risk category. This population benefits from intensive chemoimmunotherapy, consolidation with ASCT if fit, and consideration of novel agents.
A distinct subset of MCL patients (~10-15%) presents with an indolent or leukemic non-nodal phenotype characterized by SOX11 negativity, low Ki-67, mutated IGHV, and absence of TP53 mutations. These patients may remain stable for years without treatment. The MIPI may overestimate risk in this subgroup because elevated WBC (leukemic presentation) artificially inflates the score despite good prognosis. Watch-and-wait is appropriate for selected indolent MCL patients, similar to the approach for follicular lymphoma.
TP53 mutations and/or 17p deletions are present in 20-30% of MCL patients and independently predict the worst outcomes, largely overriding the MIPI score. TP53-mutated MCL is resistant to conventional chemoimmunotherapy and derives minimal benefit from ASCT. These patients should be offered clinical trials or novel combination approaches (BTK inhibitor + venetoclax, or bispecific antibodies). TP53 testing should be standard in MCL workup alongside MIPI scoring.
Minimal residual disease (MRD) monitoring using flow cytometry or PCR is emerging as a powerful tool in MCL. Achieving MRD negativity after induction correlates with prolonged PFS regardless of the initial MIPI score. MRD-guided therapy — intensifying treatment for MRD-positive patients and potentially de-escalating for MRD-negative patients — may allow personalized treatment beyond what the MIPI alone can provide.
MCL is an aggressive B-cell non-Hodgkin lymphoma characterized by the t(11;14) translocation leading to cyclin D1 overexpression. It typically presents in older males (median age ~68) with advanced-stage disease. Unlike most indolent lymphomas, MCL has a relentless relapsing course and is generally considered incurable with standard therapy, though a subset of patients with indolent/leukemic non-nodal MCL may have prolonged survival with watch-and-wait.
The International Prognostic Index (IPI) was developed for diffuse large B-cell lymphoma and does not adequately stratify MCL patients. The MIPI was specifically validated for MCL and uses a continuous mathematical formula rather than discrete point scoring. The MIPI includes WBC count (reflecting tumor burden) instead of the number of extranodal sites, which is more relevant to MCL biology.
Ki-67 is a proliferation marker expressed in actively dividing cells. In MCL, Ki-67 > 30% is associated with aggressive disease, poor treatment response, and shorter survival. The MIPI-c incorporates Ki-67 to improve prognostic accuracy. Very high Ki-67 (> 50%) is often seen in blastoid variants and may warrant consideration of intensive or novel treatment approaches.
Blastoid MCL is an aggressive morphologic variant characterized by blast-like cells with high mitotic rate. It represents 10-20% of MCL cases and carries significantly worse prognosis (median OS ~12-18 months) compared to classic MCL. Blastoid morphology often harbors TP53 mutations and high Ki-67, making it relatively refractory to standard chemoimmunotherapy. These patients should be considered for clinical trials or novel combination approaches.
BTK inhibitors (ibrutinib, acalabrutinib, zanubrutinib) have transformed relapsed/refractory MCL treatment, achieving response rates of 60-80% as single agents. They are now being studied in first-line combinations (ibrutinib + BR in SHINE trial improved PFS). Resistance to BTK inhibitors often involves BTK C481S mutations. Combination strategies (BTKi + venetoclax) show promising activity even in high-risk disease.
ASCT consolidation after intensive chemoimmunotherapy (e.g., alternating R-CHOP/R-DHAP) remains standard for fit patients < 65 years with MCL, based on improved PFS. However, the role of ASCT is being questioned in the era of BTK inhibitors and venetoclax. The ongoing TRIANGLE trial is testing whether ibrutinib-containing regimens can replace ASCT in first-line therapy. Maintenance rituximab after ASCT significantly improves PFS and OS.